# Safety and Immunogenicity of Vi-DT Typhoid Conjugate Vaccine in Indonesian Adults, Adolescents, Children and Infants

> **NCT03460405** · PHASE2 · COMPLETED · sponsor: **PT Bio Farma** · enrollment: 600 (actual)

## Conditions studied

- Safety Issues
- Immunogenicity

## Interventions

- **BIOLOGICAL:** Vi-DT Vaccine
- **BIOLOGICAL:** Vi Polysaccharide Vaccine
- **BIOLOGICAL:** IPV Vaccine

## Key facts

- **NCT ID:** NCT03460405
- **Lead sponsor:** PT Bio Farma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-07-16
- **Primary completion:** 2019-12-31
- **Final completion:** 2020-01-30
- **Target enrollment:** 600 (ACTUAL)
- **Last updated:** 2020-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03460405

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03460405, "Safety and Immunogenicity of Vi-DT Typhoid Conjugate Vaccine in Indonesian Adults, Adolescents, Children and Infants". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03460405. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*